Clopidogrel in acute coronary syndromes: where are we now?
نویسندگان
چکیده
Acute coronary syndromes (ACS) are the most common cause of death worldwide. In the United States, over 1,500,000 patients with an ACS are discharged annually (1). ACS is caused by disruption of an atherosclerotic plaque with superimposed thrombotic occlusion of the coronary artery, resulting in myocardial ischaemia or infarction. Platelets play a central role in the initiation and propagation of this process. As a result, effective anti-platelet therapy has become a cornerstone of ACS treatment. The objective of this article is to review the evidence regarding clopidogrel and its impact on the treatment of ACS in contemporary practice.
منابع مشابه
Clopidogrel and CYP2C19 testing: ready for clinical prime time?
Effective platelet inhibition has become a cornerstone in the management of patients with acute coronary syndromes (ACSs). The addition of clopidogrel, a blocker of the ADP platelet receptor, to aspirin therapy significantly reduces major cardiovascular events in ACS patients and reduces the frequency of percutaneous coronary intervention (PCI) with stent implantation. As PCI became the dominan...
متن کاملClopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond.
A comprehensive appraisal was undertaken on behalf of the British Cardiac Society and the Royal College of Physicians of London to assess the use of clopidogrel in acute coronary syndromes. The appraisal was submitted to the National Institute for Clinical Excellence (NICE) in August 2003 and contributed to the development of the recently published guidelines for the use of clopidogrel in acute...
متن کاملBivalirudin for acute coronary syndromes: premises, promises and doubts.
Bivalirudin is a valuable anticoagulant option in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention. Advantages over heparin as a parenteral anticoagulant include more predictable pharmacokinetics and pharmacodynamics, shorter half-life, no need for cofactors, some degree of antiplatelet effect, and the ability to inhibit clot-bound thrombin. Clinical ev...
متن کاملIs CURE a cure for acute coronary syndromes? Statistical versus clinical significance.
Clopidogrel has been recently approved for treatment of non-ST-elevation acute coronary syndromes based on the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial. However, the trial's findings are confounded by issues that lessen its clinical significance. Clopidogrel did not reduce mortality; its benefit was limited to preventing myocardial infarction, which was defined le...
متن کاملQuantification of peri-operative myocardial infarction after coronary artery bypass surgery.
1. Steinhubl SR, Berger PB, Mann 3rd JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–20. [Erratum JAMA 2003; 289: 987]. 2. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI–CURE and CREDO: the ‘‘Emperor’s New Clothes’’ revisited. Eur Heart J 2004;2...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Thrombosis and haemostasis
دوره 105 5 شماره
صفحات -
تاریخ انتشار 2011